Rejected from JAMA Oncology? The 7 Best Journals to Submit Next

Structured abstracts and JAMA formatting. The JAMA Network has strict formatting requirements that differ from other oncology journals. Papers that aren't formatted to JAMA specifications may be desk-rejected for administrative reasons alone. This is frustrating but preventable.

Statistical peer review. Every paper that passes desk screening at JAMA Oncology undergoes statistical review by a dedicated biostatistician. The statistical bar is high, and papers with methodological weaknesses are caught consistently. Common issues include inappropriate handling of missing data, lack of prespecified analysis plans, and confounding in observational studies.

The "importance" criterion. JAMA Network journals explicitly evaluate "importance" alongside validity. The editors aren't just asking whether your study was well-done. They're asking whether the findings matter enough to warrant publication in a limited-space journal. This subjective judgment eliminates many methodologically sound papers that the editors consider incremental.

Relevance to a broad oncology audience. JAMA Oncology targets oncologists, health policy makers, and cancer researchers. Papers that appeal only to subspecialists in a single cancer type face a higher bar than papers with cross-cutting relevance.

• "The study addresses an important question but the design limits the conclusions." JAMA Oncology is especially critical of observational study designs. Retrospective analyses, claims-based studies, and registry analyses need to demonstrate that the design is appropriate for the question and that biases are adequately controlled. If your paper used administrative data without addressing the inherent limitations of that data source, this rejection is common.

• "The findings, while novel, have limited clinical implications." Your research identified something new, but JAMA Oncology's editors couldn't see how it changes patient care. This is a framing issue. The data might genuinely matter, but the manuscript didn't connect the findings to clinical decision-making.

• "Similar findings have been published recently." JAMA Oncology publishes fewer articles per issue than JCO, which means topic saturation happens faster. If your paper's topic was recently covered, editorial space constraints can drive rejection.

• "The trial design would benefit from a randomized comparison." Single-arm trials and non-randomized comparisons face skepticism at JAMA Oncology, which strongly prefers randomized evidence for treatment comparisons. If your study was a single-arm phase II trial, the editors may have wanted a randomized design before committing journal space.

• "Better suited to JAMA Network Open." The editors think your paper is publishable but not competitive for JAMA Oncology specifically. JAMA Network Open is the JAMA Network's broad-scope open-access journal, and papers transferred there receive the same statistical and methodological review rigor.

Before choosing your next journal, a JAMA Oncology manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Journal of Clinical Oncology

JCO is the ASCO flagship and publishes more clinical oncology papers per year than JAMA Oncology. For clinical trial data, JCO is the most natural alternative because its editorial criteria focus squarely on whether the findings will change clinical practice. Where JAMA Oncology might reject a trial because it felt the study's importance didn't warrant journal space, JCO evaluates clinical significance through the lens of ASCO treatment guidelines.

If JAMA Oncology rejected your clinical trial, JCO's different editorial perspective may work in your favor. JCO also publishes more phase II trials and single-cancer-type studies than JAMA Oncology tends to accept.

Best for: Clinical oncology trials, ASCO guideline-relevant data, treatment comparison studies, phase II and III results.

2. Annals of Oncology

Annals of Oncology (ESMO) is the European counterpart to JCO and JAMA Oncology, with a comparable IF and similar editorial standards. The journal publishes landmark clinical trial results, ESMO clinical practice guidelines, and European cooperative group data. For papers with European cohort data or data from European cooperative groups, Annals may provide a better editorial match than the US-based journals.

Annals also publishes strong reviews and position papers, which can be valuable if your original research was rejected but you have enough expertise to write an authoritative review of the field.

Best for: European clinical oncology, cooperative group trials, ESMO guideline-relevant data, clinical oncology reviews.

3. Cancer

Cancer (ACS journal) covers all aspects of cancer research, from clinical trials to epidemiology to survivorship. The journal has a broader scope and higher acceptance rate than JAMA Oncology (around 20%), making it a strong mid-tier option for papers that were competitive at the top tier but didn't make the final cut.

Cancer is particularly good for outcomes research, survivorship studies, and cancer epidemiology, areas where JAMA Oncology is selective. The journal also publishes single-institution studies and retrospective analyses more readily than the top-tier journals.

Best for: Cancer epidemiology, survivorship, outcomes research, registry-based studies, all cancer types.

4. JAMA Network Open

JAMA Network Open is the JAMA Network's multidisciplinary open-access journal. Papers published here receive the same rigorous statistical and methodological review as JAMA Oncology papers, and the journal's IF (around 13) reflects its growing reputation. If JAMA Oncology suggested a transfer, JAMA Network Open is the likely destination.

The main trade-off is the APC ($3,500) and the open-access model. But JAMA Network Open's broad readership includes oncologists, primary care physicians, and health policy researchers, which can actually increase the audience for health services and disparities research compared to a specialty oncology journal.

Best for: Health services research, disparities, outcomes, comparative effectiveness, cross-specialty cancer research.

5. JNCI (Journal of the National Cancer Institute)

JNCI has a long history of publishing cancer epidemiology, cancer prevention research, and population-level cancer studies. If your JAMA Oncology submission was an epidemiological analysis, a cancer prevention trial, or a population-based outcomes study, JNCI's editorial team has deep expertise in evaluating these study types.

JNCI is pickier about study design than many journals. The editors expect epidemiological studies to use appropriate methods for their data sources and to discuss limitations transparently. But for well-designed population-based cancer research, JNCI is one of the best homes in the field.

Best for: Cancer epidemiology, prevention trials, screening research, population-based outcomes, cancer control.

6. The Lancet Oncology

Submitting to The Lancet Oncology after a JAMA Oncology rejection is an upward move in selectivity, so only do this if you're confident the paper warrants it. The Lancet Oncology accepts roughly 5% of submissions and prioritizes research with global health relevance. If your paper is a large international trial or has clear implications for cancer care in low-and-middle-income countries, The Lancet Oncology's editorial philosophy might align better than JAMA Oncology's.

This isn't the right move for most JAMA Oncology rejections. But if the rejection was about editorial fit rather than paper quality, and your research has genuine global relevance, it's worth considering.

Best for: Large international trials, global oncology, cancer research with policy implications.

7. International Journal of Cancer

IJC publishes cancer epidemiology, cancer biology, and population-based cancer research. The journal is a good option for epidemiological studies that JAMA Oncology found too specialized or for cancer biology papers with population-level implications. With an acceptance rate around 25%, IJC is more accessible than the top-tier journals while maintaining solid editorial standards.

Best for: Cancer epidemiology, cancer biology, population-based studies, international cancer data.

Randomized trial rejected? JCO first (ASCO perspective), then Annals of Oncology (ESMO perspective). Both are at the same tier as JAMA Oncology for trial data. If all three top-tier journals pass, European Journal of Cancer is the strongest mid-tier option.

Outcomes or disparities research rejected? JAMA Network Open for the same editorial rigor with broader scope. JNCI for population-based outcomes. Cancer for a broad oncology audience.

Epidemiology paper rejected? JNCI is the premier venue for cancer epidemiology. International Journal of Cancer is strong for population-based and international data.

Health services or policy research? JAMA Network Open is purpose-built for this. Health Affairs publishes cancer-relevant health policy research. Medical Care is another option for healthcare delivery research.

Non-randomized or observational study? Cancer accepts well-designed retrospective studies. JNCI values observational epidemiology. Consider whether your paper needs a randomized comparator, or whether the observational design can be presented more convincingly with better bias control methods.

Address the statistical feedback. JAMA Oncology's statistical reviewers provide specific, actionable feedback. If your paper was rejected after statistical review, those comments are gold. Fix every statistical concern before resubmitting, because other top-tier journals use similarly rigorous statistical review.

Reframe for the target audience. JAMA Oncology rejected your paper for its audience. The next journal has a different audience. Rewrite the introduction and discussion to speak to that specific readership. A paper going from JAMA Oncology to JCO needs to emphasize treatment decision-making. A paper going to JNCI needs to emphasize population-level implications.

Convert to JAMA Network Open format if offered. If the editors suggested a transfer, don't resist it. JAMA Network Open publishes excellent oncology research, and the open-access format means your paper reaches everyone, not just subscribers. The APC is worth paying for the visibility and the JAMA Network branding.

Sharpen the "importance" statement. JAMA papers include a "Key Points" box with "Question," "Findings," and "Meaning" statements. Even if the next journal doesn't require this format, thinking through those three prompts will help you articulate why your paper matters. If you can't write a compelling "Meaning" statement, the paper's significance may not be clear enough for any top-tier journal.

Fix the reporting compliance. JAMA Network journals enforce EQUATOR guidelines strictly. CONSORT for trials, STROBE for observational studies, PRISMA for reviews. Ensure every required element is present. Missing reporting items can trigger rejection at any serious journal, and they're entirely preventable.

JAMA Oncology's rejection letters often contain more useful information than most journals provide. The statistical reviewer comments alone can improve your paper substantially. Before your next submission, take the feedback seriously, revise thoroughly, and run your manuscript through a manuscript scope and readiness check to confirm scope alignment, formatting compliance, and structural completeness. The oncology publishing landscape is competitive, but papers that address reviewer feedback thoroughly and target the right journal will find the right home.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• The rejection letter mentioned "consider resubmission after revision"
• You can address every concern within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Multiple reviewers questioned novelty or significance
• Your timeline needs a decision within 2-3 months
• A specialist journal's readership would value the work more

Reframe before resubmitting anywhere if:

• Reviewers found fundamental methodology concerns
• The narrative needs restructuring, not just editing
• New experiments or analyses are needed
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting JAMA Oncology, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Clinical oncology findings without immediate practice implications. JAMA Oncology publishes work that changes what oncologists do for their patients, not work that extends understanding of what is already practiced. We see this failure as the most common pattern in JAMA Oncology desk rejections we review: well-executed clinical trials, biomarker studies, and retrospective analyses where the finding confirms current treatment approaches or identifies an association with no actionable clinical consequence. In our review of JAMA Oncology submissions, we find that editors consistently require that the clinical implications be direct and immediate, not speculative or dependent on future trials to validate.

Translational or mechanistic oncology papers without a clinical dataset. JAMA Oncology is a clinical oncology journal. Mechanistic cancer biology without patient data or an established short-term clinical translation pathway belongs at Cancer Cell, Cancer Discovery, or Nature Cancer. We see this pattern in JAMA Oncology submissions we review present preclinical findings in the context of a clinical problem without any patient data supporting the translational relevance.

Small single-institution retrospective analyses. JAMA Oncology applies a higher evidential standard than most specialty journals. Papers analyzing 50-200 patients from a single center for a clinical question where larger multi-institutional data is available face consistent desk rejection for evidential weakness. We see this failure regularly in manuscripts we review for JAMA Oncology: well-analyzed retrospective studies where the sample size and institutional scope limit the generalizability of the conclusions.

Reporting compliance gaps for oncology trials. JAMA Oncology checks CONSORT and RECIST compliance at the desk. We see this pattern in clinical trial submissions we review: missing patient disposition flowcharts, non-standardized tumor response criteria, or post-hoc endpoints presented without clear disclosure that the analysis was not pre-specified.

SciRev community data for JAMA Oncology confirms desk rejections typically arrive within days, with post-review first decisions within 4-6 weeks, consistent with the fast editorial cadence the JAMA Network maintains.